|
|
|
|
|
|
|
|
|
31.03.26 - 22:06
|
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results (Business Wire)
|
|
|
– Conference Call Today at 4:30 p.m. ETSEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include:
Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year.
Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth quarter also includes a $136.0 million non-cash charge associated with the mark-to-market adjustment on the embedded derivatives related to our 2029 Notes and Term Loan. Excluding the non-cash charge associated with the embedded derivatives, non-GAAP adjusted net income for the three months and year ...
|
|
|
|
|
26.03.26 - 13:48
|
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results.
Conference Call Details and Webcast Link Instructions
To access the live webcast, please click here or visit the “Upcoming Events” section of the Investor Relations page of Omeros' website.
A replay of the call will be available for 90 days in the “Archived Events” section of the Investor Relations page of Omeros' website.
As Omeros transitions to a new earnings call platform (hosted by Q4 Inc.), please allow extra time to log in prior to the start of the call.
About Omeros Corporation
Omeros is an innovative, commercial-stage biotechnology company that discovers and d...
|
|
|
21.03.26 - 08:24
|
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôpital Saint-Antoine, AP-HP, and will feature speakers Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, and Michelle L. Schoettler, MD, MS, Children's Healthcare of Atlanta.
The EBMT Annual Meeting is a key event for professionals in transplantation and cellular therapy, bringing together stakeholders from around the world.
About Omeros Corporation
Omeros is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics fo...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
